Boothbay Fund Management’s Seres Therapeutics MCRB Stock Holding History

Boothbay Fund Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-697	Closed	-$89K	–	2258
2022 Q3	$89K	Sell	697 -2,439	-78%	-$250K	﹤0.01%	2065
2022 Q2	$215K	Sell	3,136 -1,217	-28%	-$105K	0.01%	1689
2022 Q1	$620K	Sell	4,353 -64	-1%	-$9.84K	0.01%	1179
2021 Q4	$736K	Buy	4,417 +1,362	+45%	+$216K	0.02%	873
2021 Q3	$425K	Buy	+3,055	New	+$598K	0.01%	1162
2021 Q2	–	Sell	-2,040	Closed	-$861K	–	2007
2021 Q1	$840K	Buy	+2,040	New	+$939K	0.03%	690
2020 Q4	–	Sell	-762	Closed	-$446K	–	1347
2020 Q3	$431K	Buy	762 +182	+31%	+$60.5K	0.03%	696
2020 Q2	$55K	Buy	+580	New	+$50.9K	﹤0.01%	911

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Boothbay Fund Management's MCRB Position: Q4 2022 in Review

Boothbay Fund Management sold out of Seres Therapeutics (MCRB) in Q4 2022, closing a stake of 697 shares — an estimated $89K sold.

Boothbay Fund Management first reported a position in MCRB in Q2 2020 and held it in 8 quarters. The position peaked at $840K in Q1 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q4 2022.

Boothbay Fund Management reported no remaining Seres Therapeutics position as of Q4 2022 after selling out during the quarter.
Boothbay Fund Management sold 697 Seres Therapeutics shares in Q4 2022, an estimated $89K.
Boothbay Fund Management first reported a position in Seres Therapeutics in Q2 2020 and held it in 8 quarters.
Boothbay Fund Management's Seres Therapeutics position peaked at $840K in Q1 2021.
123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.